ArticleJMIR formative research2025
Leveraging Cognitive and Speech Ecological Momentary Assessment in Individuals With Phenylketonuria: Development and Usability Study of Cognitive Fluctuations in a Rare Disease Population.
Article in JMIR formative research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPhenylketonuria (PKU) is a rare, hereditary disease that causes disruption in phenylalanine (Phe) metabolism. Despite early intervention, individuals with PKU may have difficulty in several different cognitive domains, including verbal fluency, processing speed, and executive functioning.
objectiveThe overarching goal of this study is to characterize the relationships among cognition, speech, mood, and blood-based biomarkers (Phe, tyrosine) in individuals with early treated PKU. We describe our initial optimization pilot results that are guiding this study while establishing the feasibility and reliability of using ecological momentary assessment (EMA) in this clinical population.
methodsIn total, 20 adults with PKU were enrolled in this study between December 2022 and March 2023 through the National PKU Alliance. Of the total, 18 participants completed an extended baseline assessment followed by 6 EMAs over 1 month. The EMAs included digital cognitive tests measuring processing speed, sustained attention, and executive functioning, as well as speech (semantic fluency) and mood measures. Participants had 60 minutes to complete the assessment.
resultsCompletion rates of EMAs were above 70% (on average 4.78 out of 6 EMAs), with stable performances across baseline measures and EMAs. Between-person reliability (BPR) of the EMAs, representing the variance due to differences between individuals versus within individuals, is satisfactory with values close to (semantic fluency BPR: 0.7, sustained attention BPR: 0.72) or exceeding (processing speed: 0.93, executive functioning: 0.88) data collected from a large normative database (n=5039-10,703), as well as slightly below or matching a previous study using a clinical group (n=18). As applicable, within-person reliability was also computed; we demonstrated strong reliability for processing speed (0.87). A control analysis ensured that time of day (ie, morning, afternoon, and evening) did not impact performance; performance on tasks did not decrease if tested earlier versus later in the day (all P values >.09). Similarly, to assess variability in task performance over the course of all EMAs, the coefficient of variability was computed; 28% for the task measuring sustained attention, 37% for semantic fluency, 15.8% for the task measuring executive functioning, and 17.6% for processing speed. Performance appears more stable in tasks measuring processing speed and executive functioning than on tasks of sustained attention and semantic fluency.
conclusionsPreliminary results of this study demonstrate strong reliability of cognitive EMA, indicating that EMA is a promising tool for evaluating fluctuations in cognitive status in this population. Future work should refine and expand the utility of these digital tools, determine how variable EMA frequencies might better characterize changes in functioning as they relate to blood-based biomarkers, and validate a singular battery that could be rapidly administered at scale and in clinical trials to determine the progression of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.